These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 6198082)
21. Alkylating agents. Connors TA Cancer Chemother Biol Response Modif; 1991; 12():27-42. PubMed ID: 1931447 [No Abstract] [Full Text] [Related]
22. [The role of Thy 1.2(+)-cells in regulation of hematopoiesis during cytostatic depression]. Zhdanov VV; Aksinenko SG; Dygaĭ AM; Goldberg ED Biull Eksp Biol Med; 1998 May; 125(5):509-13. PubMed ID: 9644545 [No Abstract] [Full Text] [Related]
23. [Nephrotoxicity of anti-tumor agents]. Guelpa G Schweiz Rundsch Med Prax; 1985 May; 74(22):581-2. PubMed ID: 3925523 [No Abstract] [Full Text] [Related]
24. [Current aspects of the chemotherapy of cancer]. Vicente J Cah Med; 1971 Feb; 12(3):209-24. PubMed ID: 4930637 [No Abstract] [Full Text] [Related]
25. Genotoxicity (mitotic recombination) of the cancer chemotherapeutic agents cisplatin and cytosine arabinoside in Aspergillus nidulans. Miyamoto CT; Sant'Anna JR; Franco CC; Castro-Prado MA Food Chem Toxicol; 2007 Jun; 45(6):1091-5. PubMed ID: 17306432 [TBL] [Abstract][Full Text] [Related]
26. The current status of cancer chemotherapy. Montgomery JA Prog Drug Res; 1976; 20():465-90. PubMed ID: 796871 [No Abstract] [Full Text] [Related]
27. [New ways of the chemotherapy of cancer]. Schmidt CG Krebsarzt; 1969; 24(3):129-49. PubMed ID: 5809854 [No Abstract] [Full Text] [Related]
28. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Furukawa T; Kubota T; Tanino H; Oura S; Yuasa S; Murate H; Morita K; Kozakai K; Yano T; Hoffman RM Anticancer Res; 2000; 20(5C):3657-8. PubMed ID: 11268434 [TBL] [Abstract][Full Text] [Related]
29. [Chemotherapy of cancer]. Stock JA Recenti Prog Med; 1970 Nov; 49(5):484-506. PubMed ID: 5537629 [No Abstract] [Full Text] [Related]
30. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Mizutani Y; Yoshida O; Bonavida B J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of toxicity of intravitreal antineoplastic drugs. Peyman GA; Greenberg D; Fishman GA; Fiscella R; Thomas A Ophthalmic Surg; 1984 May; 15(5):411-3. PubMed ID: 6203076 [TBL] [Abstract][Full Text] [Related]
32. Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations. Gati WP; Larratt LM; Turner AR Proc West Pharmacol Soc; 2001; 44():93-6. PubMed ID: 11794010 [No Abstract] [Full Text] [Related]
33. The pharmacology of immunosuppressive agents. Mitchell MS; Bertino JR Conn Med; 1970 Dec; 34(12):843-50. PubMed ID: 4923392 [No Abstract] [Full Text] [Related]
34. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Tikoo K; Ali IY; Gupta J; Gupta C Toxicol Lett; 2009 Dec; 191(2-3):158-66. PubMed ID: 19723570 [TBL] [Abstract][Full Text] [Related]
35. Cancer chemotherapy: implications for the anesthesiologist. Selvin BL Anesth Analg; 1981 Jun; 60(6):425-34. PubMed ID: 7015924 [No Abstract] [Full Text] [Related]
36. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations. Kim K; Blechman WJ; Riddle VG; Pardee AB Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006 [TBL] [Abstract][Full Text] [Related]
37. [Membrane transport of antineoplastic drugs and its relevance to tumour chemotherapy (author's transl)]. Kolassa N Wien Klin Wochenschr; 1980; 92(20):707-15. PubMed ID: 7467345 [TBL] [Abstract][Full Text] [Related]
38. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534 [TBL] [Abstract][Full Text] [Related]
39. Stage-specific sensitivity of spermatogonia to different chemotherapeutic drugs. Meistrich ML Biomed Pharmacother; 1984; 38(3):137-42. PubMed ID: 6478053 [TBL] [Abstract][Full Text] [Related]
40. Haloenol lactone: a new synergist of chemotherapy in vitro. Zheng J; Wurz GT; Cadman TB; Degregorio MW; Jones AD; Hammock BD Biochem Biophys Res Commun; 1997 Dec; 241(1):13-7. PubMed ID: 9405226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]